NCT02629393 - Study of ORGN001 (Formerly ALXN1101) in Neonates, Infants and Children With Molybdenum Cofactor Deficiency (MOCD) Type A | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2016

Primary Completion Date

September 30, 2022

Study Completion Date

October 31, 2022

Conditions

Molybdenum Cofactor Deficiency, Type A

Interventions

DRUG

ORGN001 (formerly ALXN1101)

Trial Locations (11)

HaEmek Medical Center, Afula

Cincinnati Children's Hospital Medical Center, Cincinnati

Children's Hosptial of Michigan, Detroit

Children's Hospital of Wisconsin, Milwaukee

Stavanger Universitetssjukehus, Stavanger

Gazi University, Ankara

Great Ormond Street Hosptial, London

Hospital Sant Joan de Deu, Esplugues de Llobregat

Hacettepe University of Medicine, Ankara

Akdeniz University Medical Faculty, Antalya

Willink Biochemical Genetics Unit, Manchester